Abstracts Archive - Page 350 of 1683 - ATC Abstracts

2020 American Transplant Congress
The Role of Complement-Split Products as Biomarkers for Acute Antibody-Mediated Rejection of Kidney Allografts
B. G. Abu Jawdeh¹, B. Campos-Naciff¹, K. Harrison¹, K. Meganathan¹, A. Kumar², M. Anand¹, A. Govil¹, E. S. Woodle¹, B. P. Dixon³
¹University of Cincinnati, Cincinnati, OH, ²All India Institute of Medical Sciences, New Delhi, India, ³University of Colorado, Aurora, CO
*Purpose: Acute antibody-mediated rejection (AMR) is mediated by the activation of the classical complement system in addition to non-complement dependent inflammatory pathways. Complement fixation by…
2020 American Transplant Congress
Characterization of an Integrative Prognostic Score for US Patients Taken from the DART Study
J. Bromberg¹, R. Bloom², P. Sood³
¹University of Maryland, Baltimore, MD, ²Penn Medicine, Philadelphia, PA, ³University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: iBox is a validated cloud-based software as a service (SaaS) algorithm that provides a predictive analysis of the post-transplant patient, quantifying the risk of…
2020 American Transplant Congress
Epidemiology of Non-Aspergillus Mold in Lung Transplant Recipients at a Large Transplant Center
J. A. Morillas¹, F. J. Marco Canosa¹, H. Hassouna², K. Brizendine¹
¹Infectious Disease, Cleveland Clinic Foundation, Cleveland, OH, ²Infectious Disease, Spectrum Health Medical Group-Michigan State University College of Human Medicine, Grand Rapids, MI
*Purpose: Invasive fungal infections (IFI) remain a significant cause of mortality among lung transplant recipients (LTR). The emergence of non-Aspergillus molds has become a concern…
2020 American Transplant Congress
Donor-Derived Cell-Free DNA May Not Discriminate Rejection in Kidney Transplant Recipients with a Prior Allograft in Place
A. Vo, M. Gillespie, S. C. Jordan, A. Peng, R. Najjar, S. Sethi, K. Lim, N. Ammerman, E. Huang
Cedars-Sinai, Los Angeles, CA
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) is an injury biomarker discriminating rejection in kidney transplant (KTx) patients (pts). However, its performance when stratified by rejection risk…
2020 American Transplant Congress
Simultaneously Detection of ddcfDNA in Plasma and Urine Assist to Determine the Type of Rejection in Renal Transplant Patients
D. Cheng¹, F. Liu², H. Liu², T. Jiang², Y. Zhou³, L. Shu², X. Li¹, K. Xie¹, X. Ni¹, J. Chen¹, J. Ge², Z. Liu¹, H. Shi³
¹Jinling Hospital Nanjing University, Nanjing, China, ²AlloDx, Shanghai; Suzhou, China, ³Jiangsu University, Zhenjiang, China
*Purpose: The correct diagnosis and treatment of acute rejection (ABMR and TCMR) are the key to the long-term survival after renal transplantation. Renal biopsy is…
2020 American Transplant Congress
The Plasma DdcfDNA Level Associates with the Pathological Characteristics in Renal Allograft
R. Wang, J. Shen, J. Wu, J. Chen
Kidney Disease Center, First Affiliated Hospital of Zhejiang University, Hangzhou, China
*Purpose: Donor-derived cell-free DNA (ddcfDNA) is a promising biomarker for monitoring the allograft health status, however, its relationship with the pathological characteristics is still elusive.*Methods:…
2020 American Transplant Congress
The Frequency of De Novo DSA in the Years Following Heart Transplantation
A. Shen, J. Patel, M. Kittleson, D. Chang, E. Kransdorf, D. Geft, K. Nishihara, L. Czer, F. Esmailian, J. A. Kobashigawa
Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
*Purpose: The timing of the development of donor specific antibody (DSA) after heart transplantation is not clear. De novo DSA has been reported to be…
2020 American Transplant Congress
Donor-Derived Cell-Free DNA Levels During Early Rejection after Kidney Transplant May Be Impacted by Type of Induction Agent Received
M. Gillespie, K. Lim, A. Vo, E. Huang, N. Ammerman, A. Peng, R. Najjar, S. Sethi, S. Jordan
Cedars-Sinai, Los Angeles, CA
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) is an injury biomarker that detects rejection in kidney transplant recipients (KTR). It is reported as % cfDNA from the…
2020 American Transplant Congress
Incidence of Fragility Fractures and Changes in Bone Mineral Density in Type 1 Diabetes Recipients of Pancreas Transplant Alone
Y. C. Kudva, S. Batthula, R. Kaur, B. H. Smith, S. R. Rizvi, P. G. Dean, W. K. Kremers, M. D. Stegall, R. A. Wermers
Mayo Clinic, Rochester, MN
*Purpose: Type 1 Diabetes (T1D) is associated with increased fracture risk. Solid organ transplant recipients are at high risk for fracture but limited data are…
2020 American Transplant Congress
Resilience in Heart Transplant Candidates
Y. T. Bui¹, D. S. Yip², B. W. Hardaway³, S. M. Dunlay⁴, S. Jowsey-Gregoire⁵, R. Benzo⁶, R. C. Daly⁷, M. A. Hathcock⁸, K. Thompson⁹, C. C. Kennedy¹⁰
¹Mayo Clinic Alix School of Medicine, Rochester, MN, ²Department of Transplantation, Mayo Clinic, Jacksonville, FL, ³Division of Cardiovascular Diseases, Mayo Clinic, Scottsdale, AZ, ⁴Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, ⁵Department of Psychiatry, Mayo Clinic, Rochester, MN, ⁶Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ⁷Division of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, ⁸Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, ⁹Pulmonary Clinical Research Unit, Mayo Clinic, Rochester, MN, ¹⁰William J. von Liebig Center for Transplantation and Regenerative Medicine, Mayo Clinic, Rochester, MN
*Purpose: Resilience is the capacity to adapt to or recover from adverse experiences. Our objective was to measure resilience in waitlisted, adult heart transplant candidates…